SIMILAR PATTERNS OF AMINO ACIDS FOR 4AGC_A_AXIA2000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 LYS A 222 GLU A 236 GLY A 272 LEU A 321	None	0.54A	4agcA-1k9aA: 30.9	4agcA-1k9aA: 29.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 267 VAL A 275 ALA A 288 LYS A 290 GLU A 305 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) P16 A 2 (-4.5A) P16 A 2 (-4.2A) P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.47A	4agcA-1opkA: 30.2	4agcA-1opkA: 28.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1q8y	SR PROTEIN KINASE (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 164 VAL A 172 ALA A 185 LYS A 187 LEU A 206 LEU A 301	ADP A 810 ( 4.3A) ADP A 810 (-4.1A) ADP A 810 (-3.3A) ADP A 810 (-3.1A) None ADP A 810 (-4.7A)	0.58A	4agcA-1q8yA: 20.6	4agcA-1q8yA: 23.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1rjb	FL CYTOKINE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 818 CYH A 828	None	0.53A	4agcA-1rjbA: 42.2	4agcA-1rjbA: 47.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1t46	HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 595 VAL A 603 ALA A 621 LYS A 623 GLU A 640 LEU A 644 GLY A 676 LEU A 799 CYH A 809 PHE A 811	STI A 3 ( 3.8A) STI A 3 ( 4.6A) STI A 3 (-3.5A) STI A 3 (-3.7A) STI A 3 (-3.6A) STI A 3 (-4.4A) STI A 3 ( 3.8A) STI A 3 (-4.4A) STI A 3 (-4.5A) STI A 3 (-3.6A)	0.48A	4agcA-1t46A: 42.9	4agcA-1t46A: 49.44
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 344 VAL A 352 ALA A 367 GLU A 386 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) None STU A 100 (-3.5A) STU A 100 (-4.5A)	0.49A	4agcA-1u59A: 31.0	4agcA-1u59A: 30.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u5q	SERINE/THREONINE PROTEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 GLU A 76 LEU A 80 GLY A 110 LEU A 158	None	0.56A	4agcA-1u5qA: 23.2	4agcA-1u5qA: 27.97
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLU A 55 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-4.3A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) None None HYM A 400 (-4.5A)	0.50A	4agcA-1zltA: 20.5	4agcA-1zltA: 23.90
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2a2a	DEATH-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 68	None None GOL A3001 (-3.5A) None None None	0.53A	4agcA-2a2aA: 21.9	4agcA-2a2aA: 25.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU X 17 VAL X 25 ALA X 37 LYS X 39 GLU X 54 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) STU X 902 (-3.1A) STU X 902 ( 4.4A) STU X 902 (-3.5A) STU X 902 (-4.4A)	0.60A	4agcA-2dq7X: 30.7	4agcA-2dq7X: 32.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2eu9	DUAL SPECIFICITY PROTEIN KINASE CLK3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 162 VAL A 170 ALA A 184 LYS A 186 GLU A 201 LEU A 205	None	0.58A	4agcA-2eu9A: 21.6	4agcA-2eu9A: 22.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 59 LEU A 63	ADP A 500 (-4.3A) ADP A 500 (-4.3A) ADP A 500 ( 3.7A) ADP A 500 (-2.9A) None None	0.53A	4agcA-2f9gA: 3.5	4agcA-2f9gA: 25.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2gcd	SERINE/THREONINE-PRO TEIN KINASE TAO2 (Rattus norvegicus)	PF00069 (Pkinase)	6	VAL A 42 ALA A 55 GLU A 76 LEU A 80 GLY A 110 LEU A 158	STU A 400 ( 4.8A) STU A 400 (-3.2A) None None STU A 400 (-3.4A) STU A 400 ( 4.6A)	0.58A	4agcA-2gcdA: 24.0	4agcA-2gcdA: 26.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 55 VAL A 63 ALA A 76 GLY A 130 LEU A 177 CYH A 190	None	0.37A	4agcA-2hw6A: 20.3	4agcA-2hw6A: 24.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hw6	MAP KINASE-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 55 VAL A 63 LYS A 78 LEU A 98 GLY A 130 LEU A 177 CYH A 190	None	0.62A	4agcA-2hw6A: 20.3	4agcA-2hw6A: 24.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 LYS A 271 GLU A 286 GLY A 321 LEU A 370 PHE A 382	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-3.6A) None GIN A 600 (-4.7A) GIN A 600 (-4.0A)	0.42A	4agcA-2hz0A: 31.6	4agcA-2hz0A: 35.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2iwi	SERINE/THREONINE-PRO TEIN KINASE PIM-2 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 38 VAL A 46 ALA A 59 GLU A 83 LEU A 87 LEU A 170	HB1 A1289 ( 4.1A) HB1 A1289 (-3.6A) HB1 A1289 ( 3.7A) None None HB1 A1289 (-4.7A)	0.58A	4agcA-2iwiA: 21.0	4agcA-2iwiA: 24.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 588 VAL A 596 ALA A 614 GLU A 633 GLY A 669 LEU A 785	None	0.50A	4agcA-2ogvA: 41.0	4agcA-2ogvA: 48.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 588 VAL A 596 ALA A 614 LYS A 616 GLU A 633 GLY A 669	None	0.53A	4agcA-2ogvA: 41.0	4agcA-2ogvA: 48.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	LEU A 25 VAL A 33 ALA A 46 LEU A 77 GLY A 109 LEU A 156	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A)	0.47A	4agcA-2phkA: 21.8	4agcA-2phkA: 23.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	LEU A 25 VAL A 33 LYS A 48 LEU A 77 GLY A 109 LEU A 156	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.2A) None None ATP A 381 ( 4.8A)	0.52A	4agcA-2phkA: 21.8	4agcA-2phkA: 23.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 GLU A 534 VAL A 564 GLY A 570 LEU A 633	None	0.55A	4agcA-2psqA: 34.5	4agcA-2psqA: 50.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 ALA A 749 LYS A 751 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.58A	4agcA-2r4bA: 28.9	4agcA-2r4bA: 35.28
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2w4k	DEATH-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 68	ADP A1303 ( 3.9A) ADP A1303 (-4.0A) ADP A1303 (-3.5A) ADP A1303 (-2.7A) ADP A1303 ( 4.8A) None	0.58A	4agcA-2w4kA: 21.9	4agcA-2w4kA: 25.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xik	SERINE/THREONINE PROTEIN KINASE 25 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 34 ALA A 47 GLU A 66 LEU A 70 GLY A 101 LEU A 147	J60 A1294 ( 4.9A) J60 A1294 (-3.3A) None None J60 A1294 ( 3.8A) J60 A1294 (-4.8A)	0.55A	4agcA-2xikA: 17.8	4agcA-2xikA: 27.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2yab	DEATH-ASSOCIATED PROTEIN KINASE 2 (Mus musculus)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 LYS A 42 GLU A 64 LEU A 68	AMP A1302 (-3.7A) AMP A1302 (-4.2A) AMP A1302 (-3.6A) AMP A1302 (-2.8A) None None	0.60A	4agcA-2yabA: 21.9	4agcA-2yabA: 25.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 68 VAL A 76 ALA A 92 LYS A 94 GLY A 147 LEU A 194	STU A 1 (-3.8A) None STU A 1 (-3.3A) STU A 1 (-2.8A) STU A 1 ( 3.9A) STU A 1 (-4.6A)	0.44A	4agcA-2z7rA: 21.3	4agcA-2z7rA: 27.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 487 VAL A 495 ALA A 515 LYS A 517 VAL A 564 GLY A 570 LEU A 633	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.5A) None M33 A1996 ( 4.8A) M33 A1996 (-4.5A)	0.46A	4agcA-3b2tA: 24.9	4agcA-3b2tA: 49.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3c4f	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 484 VAL A 492 ALA A 512 GLU A 531 VAL A 561 GLY A 567 LEU A 630	C4F A 1 ( 3.9A) None C4F A 1 (-3.3A) None C4F A 1 ( 4.8A) None C4F A 1 (-4.6A)	0.59A	4agcA-3c4fA: 33.4	4agcA-3c4fA: 54.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 LYS A 222 GLU A 236 GLY A 272 LEU A 321	None	0.54A	4agcA-3d7uA: 25.2	4agcA-3d7uA: 32.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3f2a	PROTO-ONCOGENE SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 44 VAL A 52 ALA A 65 LYS A 67 GLU A 89 LEU A 93 LEU A 174	985 A 1 (-4.1A) 985 A 1 (-4.5A) 985 A 1 (-3.5A) 985 A 1 ( 2.8A) MG A 314 (-3.6A) MG A 314 ( 4.8A) 985 A 1 (-4.8A)	0.54A	4agcA-3f2aA: 16.3	4agcA-3f2aA: 28.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3hng	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	11	LEU A 833 VAL A 841 ALA A 859 LYS A 861 GLU A 878 LEU A 882 VAL A 909 GLY A 915 LEU A1029 CYH A1039 PHE A1041	8ST A2001 ( 4.7A) 8ST A2001 ( 4.6A) 8ST A2001 ( 3.8A) 8ST A2001 (-4.0A) 8ST A2001 (-3.7A) None 8ST A2001 (-4.1A) None None 8ST A2001 (-4.2A) 8ST A2001 ( 3.7A)	0.51A	4agcA-3hngA: 42.0	4agcA-3hngA: 67.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 49 VAL A 57 ALA A 70 GLU A 91 LEU A 95 GLY A 126 LEU A 173	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None None XFE A 351 (-4.6A)	0.52A	4agcA-3mvjA: 20.8	4agcA-3mvjA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mvj	CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 49 VAL A 57 ALA A 70 LYS A 72 GLU A 91 LEU A 95	XFE A 351 (-4.2A) XFE A 351 ( 4.5A) XFE A 351 (-3.2A) None None None	0.52A	4agcA-3mvjA: 20.8	4agcA-3mvjA: 25.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 88 VAL A 96 ALA A 109 LYS A 111 GLU A 130 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 ( 4.7A) JOZ A 361 (-3.4A) SO4 A 5 (-2.8A) SO4 A 5 (-3.1A) None None	0.51A	4agcA-3nuuA: 22.6	4agcA-3nuuA: 25.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 192 VAL A 200 ALA A 213 LYS A 215 GLU A 234 LEU A 238 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None None None AMP A 577 (-4.8A)	0.76A	4agcA-3nyoA: 21.1	4agcA-3nyoA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 ALA A 751 LYS A 753 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) 03Q A 1 (-4.7A) 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.50A	4agcA-3pp0A: 29.7	4agcA-3pp0A: 28.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3q5i	PROTEIN KINASE (Plasmodium berghei)	PF00069 (Pkinase) PF13499 (EF-hand_7)	7	LEU A 63 VAL A 71 ALA A 84 LYS A 86 LEU A 119 GLY A 150 LEU A 197	ANP A1634 ( 4.3A) ANP A1634 (-4.1A) ANP A1634 (-3.6A) ANP A1634 (-3.1A) None None ANP A1634 (-4.4A)	0.55A	4agcA-3q5iA: 19.6	4agcA-3q5iA: 22.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3tt0	BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 GLU A 531 VAL A 561 GLY A 567 LEU A 630	07J A 1 ( 4.3A) 07J A 1 (-4.0A) 07J A 1 (-3.5A) 07J A 1 (-4.5A) 07J A 1 (-3.8A) 07J A 1 (-4.7A) 07J A 1 (-3.7A) 07J A 1 ( 4.4A)	0.60A	4agcA-3tt0A: 34.6	4agcA-3tt0A: 50.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 361 VAL A 369 ALA A 382 GLU A 403 LEU A 407 GLY A 439 LEU A 486	07U A 1 ( 4.8A) 07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 ( 4.8A) None None 07U A 1 (-4.3A)	0.68A	4agcA-3txoA: 13.1	4agcA-3txoA: 23.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3txo	PROTEIN KINASE C ETA TYPE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 361 VAL A 369 ALA A 382 LYS A 384 GLU A 403 LEU A 407 LEU A 486	07U A 1 ( 4.8A) 07U A 1 (-4.8A) 07U A 1 (-3.3A) 07U A 1 (-3.0A) 07U A 1 ( 4.8A) None 07U A 1 (-4.3A)	0.65A	4agcA-3txoA: 13.1	4agcA-3txoA: 23.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 840 VAL A 848 ALA A 866 GLU A 885 LEU A 889 VAL A 916 GLY A 922 LEU A1035 CYH A1045	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None 4TT A2001 (-3.7A) 4TT A2001 (-4.8A) None	0.44A	4agcA-3vidA: 30.0	4agcA-3vidA: 85.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3vid	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 840 VAL A 848 ALA A 866 LYS A 868 GLU A 885 LEU A 889 VAL A 916	4TT A2001 ( 4.0A) 4TT A2001 ( 4.5A) 4TT A2001 (-3.5A) None None None None	0.56A	4agcA-3vidA: 30.0	4agcA-3vidA: 85.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3wzd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 840 VAL A 848 ALA A 866 GLU A 885 LEU A 889 VAL A 916 GLY A 922 LEU A1035 CYH A1045	LEV A1201 ( 3.8A) LEV A1201 ( 4.9A) LEV A1201 (-3.5A) LEV A1201 (-3.7A) LEV A1201 ( 4.4A) LEV A1201 ( 4.6A) LEV A1201 (-3.6A) LEV A1201 (-4.8A) GOL A1210 ( 3.3A)	0.46A	4agcA-3wzdA: 38.3	4agcA-3wzdA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ILE A 804 LEU A 840 VAL A 848 ALA A 866 GLU A 885 VAL A 916 GLY A 922 LEU A1035 CYH A1045 PHE A1047	None B49 A2000 (-3.7A) None B49 A2000 (-3.5A) None B49 A2000 (-4.8A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A) B49 A2000 ( 4.1A) B49 A2000 (-4.0A)	0.42A	4agcA-4agdA: 48.6	4agcA-4agdA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	ILE A 804 LEU A 840 VAL A 848 ALA A 866 LYS A 868 GLU A 885 GLY A 922 LEU A1035 CYH A1045 PHE A1047	None B49 A2000 (-3.7A) None B49 A2000 (-3.5A) B49 A2000 (-3.0A) None B49 A2000 ( 3.7A) B49 A2000 (-4.5A) B49 A2000 ( 4.1A) B49 A2000 (-4.0A)	0.52A	4agcA-4agdA: 48.6	4agcA-4agdA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 840 VAL A 848 ALA A 866 GLU A 885 LEU A 889 VAL A 916 GLY A 922 LEU A1035 CYH A1045 PHE A1047	B49 A2000 (-3.7A) None B49 A2000 (-3.5A) None None B49 A2000 (-4.8A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A) B49 A2000 ( 4.1A) B49 A2000 (-4.0A)	0.45A	4agcA-4agdA: 48.6	4agcA-4agdA: 100.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	10	LEU A 840 VAL A 848 ALA A 866 LYS A 868 GLU A 885 LEU A 889 GLY A 922 LEU A1035 CYH A1045 PHE A1047	B49 A2000 (-3.7A) None B49 A2000 (-3.5A) B49 A2000 (-3.0A) None None B49 A2000 ( 3.7A) B49 A2000 (-4.5A) B49 A2000 ( 4.1A) B49 A2000 (-4.0A)	0.56A	4agcA-4agdA: 48.6	4agcA-4agdA: 100.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4agu	CYCLIN-DEPENDENT KINASE-LIKE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 18 ALA A 31 LYS A 33 GLU A 51 LEU A 55 LEU A 133 CYH A 143	D15 A 500 (-4.6A) D15 A 500 (-3.4A) D15 A 500 ( 4.1A) None None D15 A 500 (-4.5A) D15 A 500 ( 4.0A)	0.60A	4agcA-4aguA: 22.2	4agcA-4aguA: 25.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4aw2	SERINE/THREONINE-PRO TEIN KINASE MRCK ALPHA (Rattus norvegicus)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	VAL A 91 ALA A 104 LYS A 106 GLU A 125 LEU A 129 GLY A 160 LEU A 208	None EDO A1420 (-3.4A) EDO A1419 (-3.3A) EDO A1419 (-3.0A) None None EDO A1420 ( 4.8A)	0.68A	4agcA-4aw2A: 19.3	4agcA-4aw2A: 22.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 VAL A 254 ALA A 267 GLU A 288 LEU A 292 GLY A 324 LEU A 371	None	0.75A	4agcA-4c0tA: 22.0	4agcA-4c0tA: 16.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c0t	LIKELY PROTEIN KINASE (Candida albicans)	PF00069 (Pkinase)	7	LEU A 246 VAL A 254 ALA A 267 LYS A 269 LEU A 292 GLY A 324 LEU A 371	None	0.60A	4agcA-4c0tA: 22.0	4agcA-4c0tA: 16.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 663 VAL A 671 ALA A 684 LYS A 686 GLY A 743 LEU A 789	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) AGS A1985 (-3.0A) None AGS A1985 (-4.8A)	0.52A	4agcA-4crsA: 15.2	4agcA-4crsA: 23.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4eut	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLU A 55 LEU A 59 GLY A 92	BX7 A 401 (-3.7A) BX7 A 401 (-4.4A) BX7 A 401 (-3.4A) BX7 A 401 ( 4.0A) None None BX7 A 401 (-3.5A)	0.51A	4agcA-4eutA: 19.3	4agcA-4eutA: 22.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4euu	SERINE/THREONINE-PRO TEIN KINASE TBK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 VAL A 23 ALA A 36 LYS A 38 GLU A 55 LEU A 59 GLY A 92	BX7 A 401 (-3.9A) BX7 A 401 ( 4.6A) BX7 A 401 (-3.4A) BX7 A 401 (-3.5A) None None BX7 A 401 (-3.3A)	0.43A	4agcA-4euuA: 21.6	4agcA-4euuA: 24.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 LYS A 402 GLU A 420 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.89A	4agcA-4f4pA: 30.0	4agcA-4f4pA: 34.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4f99	CELL DIVISION CYCLE 7-RELATED PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 72 ALA A 88 LYS A 90 GLU A 104 LEU A 108 LEU A 184	ADP A 601 (-4.0A) ADP A 601 (-3.5A) ADP A 601 (-2.6A) None None ADP A 601 ( 4.9A)	0.55A	4agcA-4f99A: 13.7	4agcA-4f99A: 22.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1122 VAL A1130 ALA A1148 LYS A1150 GLU A1167 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) 0UV A1501 (-3.7A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.88A	4agcA-4fodA: 24.4	4agcA-4fodA: 33.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g3f	NF-KAPPA-BETA-INDUCI NG KINASE (Mus musculus)	PF00069 (Pkinase)	6	VAL A 416 ALA A 429 GLU A 442 GLY A 477 LEU A 524 CYH A 535	0WB A 701 (-4.4A) 0WB A 701 (-3.3A) 0WB A 701 (-3.2A) 0WB A 701 ( 4.5A) 0WB A 701 (-4.3A) 0WB A 701 ( 3.7A)	0.53A	4agcA-4g3fA: 21.3	4agcA-4g3fA: 25.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gv1	RAC-ALPHA SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 156 VAL A 164 ALA A 177 LYS A 179 GLU A 198 LEU A 202 GLY A 233	0XZ A 501 ( 4.1A) 0XZ A 501 (-4.5A) 0XZ A 501 (-3.3A) GOL A 503 ( 2.8A) GOL A 503 (-3.6A) None None	0.67A	4agcA-4gv1A: 20.6	4agcA-4gv1A: 23.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 828 VAL A 836 ALA A 853 LYS A 855 GLU A 871 GLY A 908 LEU A 956	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-3.5A) None 19S A1201 ( 3.8A) 19S A1201 (-4.5A)	0.44A	4agcA-4hviA: 29.8	4agcA-4hviA: 31.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259	None	0.43A	4agcA-4hzsA: 27.0	4agcA-4hzsA: 30.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 VAL A 140 ALA A 156 LYS A 158 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.47A	4agcA-4id7A: 29.4	4agcA-4id7A: 33.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 406 VAL A 414 LYS A 429 GLU A 440 GLY A 475 LEU A 522 CYH A 533	T28 A 701 (-3.8A) T28 A 701 (-4.7A) T28 A 701 ( 3.8A) None T28 A 701 ( 3.0A) T28 A 701 (-3.9A) T28 A 701 (-3.7A)	0.74A	4agcA-4idtA: 21.5	4agcA-4idtA: 26.84
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 18 VAL A 26 ALA A 39 LYS A 41 GLY A 95 LEU A 143	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 (-2.7A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A)	0.53A	4agcA-4jxfA: 8.5	4agcA-4jxfA: 23.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 478 VAL A 486 ALA A 506 LYS A 508 GLU A 525 VAL A 555 GLY A 561 LEU A 624	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 (-2.7A) ACP A 801 ( 4.8A) ACP A 801 (-4.7A) ACP A 801 ( 4.6A) ACP A 801 (-4.4A)	0.63A	4agcA-4k33A: 25.9	4agcA-4k33A: 51.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4l52	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	VAL A 50 ALA A 61 GLU A 77 LEU A 81 GLY A 110 LEU A 163 CYH A 174	1UL A 501 ( 4.9A) 1UL A 501 (-3.1A) None None 1UL A 501 ( 3.7A) 1UL A 501 (-4.3A) 1UL A 501 (-3.6A)	0.62A	4agcA-4l52A: 19.2	4agcA-4l52A: 28.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	7	VAL B 38 ALA B 51 LYS B 53 GLU B 70 LEU B 74 GLY B 105 LEU B 151	ADP B 500 (-4.5A) ADP B 500 (-3.3A) ADP B 500 (-3.1A) None None None ADP B 500 (-4.7A)	0.75A	4agcA-4o27B: 17.1	4agcA-4o27B: 25.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	LEU A 46 VAL A 54 ALA A 67 LYS A 69 GLU A 85 GLY A 128 LEU A 180 CYH A 190	SIN A 401 ( 3.9A) None SIN A 401 ( 3.7A) None None SIN A 401 (-3.5A) SIN A 401 ( 4.5A) None	0.68A	4agcA-4o38A: 20.0	4agcA-4o38A: 24.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 GLU A 947 GLY A 984 LEU A1030	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) None 2TT A1202 (-3.4A) 2TT A1202 (-4.4A)	0.45A	4agcA-4oliA: 27.5	4agcA-4oliA: 24.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 627 VAL A 635 ALA A 648 LEU A 673 GLY A 707 LEU A 753	None	0.53A	4agcA-4otdA: 21.2	4agcA-4otdA: 26.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4q9z	HUMAN PROTEIN KINASE C THETA (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	6	LEU A 386 VAL A 394 ALA A 407 LYS A 409 LEU A 432 LEU A 511	PZW A 801 (-3.9A) PZW A 801 (-4.6A) PZW A 801 (-3.5A) None None PZW A 801 (-4.8A)	0.57A	4agcA-4q9zA: 19.6	4agcA-4q9zA: 24.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-3.8A) None P30 A1001 (-3.4A) P30 A1001 (-3.4A) P30 A1001 (-3.6A) P30 A1001 (-3.4A) P30 A1001 (-4.6A) P30 A1001 (-4.1A) P30 A1001 (-3.9A)	0.30A	4agcA-4rt7A: 31.3	4agcA-4rt7A: 43.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	7	LEU A 104 VAL A 112 ALA A 125 LYS A 127 GLU A 146 GLY A 181 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) ATP A 501 (-2.6A) None None ATP A 501 (-4.5A)	0.56A	4agcA-4wb7A: 20.6	4agcA-4wb7A: 23.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wb7	DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA (Homo sapiens)	PF00069 (Pkinase) PF00226 (DnaJ)	7	LEU A 104 VAL A 112 ALA A 125 LYS A 127 LEU A 150 GLY A 181 LEU A 228	ATP A 501 ( 4.3A) ATP A 501 (-4.0A) ATP A 501 (-3.4A) ATP A 501 (-2.6A) None None ATP A 501 (-4.5A)	0.60A	4agcA-4wb7A: 20.6	4agcA-4wb7A: 23.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 VAL A 201 ALA A 214 LYS A 216 LEU A 239 GLY A 270 LEU A 321	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.62A	4agcA-4wboA: 22.0	4agcA-4wboA: 21.21
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 52 VAL A 60 ALA A 72 GLY A 132 LEU A 183 CYH A 193	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) KSA A 405 (-3.4A)	0.36A	4agcA-4wsqA: 22.5	4agcA-4wsqA: 24.38
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xcu	FIBROBLAST GROWTH FACTOR RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 473 VAL A 481 ALA A 501 LYS A 503 GLU A 520 VAL A 550	40M A1002 ( 4.6A) 40M A1002 ( 4.5A) 40M A1002 ( 4.1A) 40M A1002 (-4.0A) 40M A1002 (-3.7A) 40M A1002 (-4.7A)	0.59A	4agcA-4xcuA: 33.7	4agcA-4xcuA: 47.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 GLU A 661 GLY A 697 LEU A 818 CYH A 828 PHE A 830	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 (-3.1A) P30 A1001 (-3.5A) P30 A1001 (-4.3A) P30 A1001 (-4.8A) P30 A1001 ( 4.1A)	0.59A	4agcA-4xufA: 39.1	4agcA-4xufA: 51.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xuf	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 616 VAL A 624 ALA A 642 LYS A 644 GLU A 661 GLY A 697 LEU A 818 PHE A 830	P30 A1001 (-4.0A) P30 A1001 ( 4.8A) P30 A1001 (-3.5A) P30 A1001 ( 4.0A) P30 A1001 (-3.1A) P30 A1001 (-3.5A) P30 A1001 (-4.3A) P30 A1001 ( 4.1A)	0.72A	4agcA-4xufA: 39.1	4agcA-4xufA: 51.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	8	LEU A 34 VAL A 42 ALA A 55 LYS A 57 GLU A 76 LEU A 80 GLY A 111 LEU A 158	ADP A 506 ( 3.8A) ADP A 506 (-4.3A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) None None None ADP A 506 (-4.7A)	0.53A	4agcA-4ysjA: 21.9	4agcA-4ysjA: 23.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 484 VAL A 492 ALA A 512 LYS A 514 GLU A 531 VAL A 561 GLY A 567 LEU A 630	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 ( 3.1A) EDO A1766 (-4.1A) 38O A1769 (-4.3A) 38O A1769 (-3.4A) 38O A1769 (-4.6A)	0.60A	4agcA-5a46A: 34.6	4agcA-5a46A: 45.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5e8y	TGF-BETA RECEPTOR TYPE-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 258 ALA A 275 LYS A 277 GLY A 331 LEU A 386 CYH A 396	STU A 601 (-4.0A) STU A 601 (-3.1A) STU A 601 (-2.4A) STU A 601 (-3.5A) STU A 601 (-3.9A) STU A 601 (-3.2A)	0.46A	4agcA-5e8yA: 24.3	4agcA-5e8yA: 27.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	6	LEU A 99 VAL A 107 ALA A 120 LYS A 122 GLY A 176 LEU A 223	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A)	0.36A	4agcA-5eykA: 22.1	4agcA-5eykA: 25.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 903 VAL A 911 ALA A 928 LYS A 930 GLU A 947 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) None None 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.53A	4agcA-5f1zA: 28.2	4agcA-5f1zA: 28.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 ALA A 756 LYS A 758 GLU A 775 LEU A 779 VAL A 804	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) PP1 A2012 (-3.5A) None PP1 A2012 (-4.5A)	0.64A	4agcA-5fm2A: 32.4	4agcA-5fm2A: 41.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 ALA A 756 LYS A 758 LEU A 779 VAL A 804 GLY A 810	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) None PP1 A2012 (-4.5A) PTR A 809 (-2.4A)	0.65A	4agcA-5fm2A: 32.4	4agcA-5fm2A: 41.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fm2	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 730 VAL A 738 ALA A 756 LYS A 758 VAL A 804 GLY A 810 LEU A 881	PP1 A2012 (-4.6A) PP1 A2012 (-4.4A) PP1 A2012 (-3.2A) PP1 A2012 (-4.1A) PP1 A2012 (-4.5A) PTR A 809 (-2.4A) PP1 A2012 (-4.6A)	0.61A	4agcA-5fm2A: 32.4	4agcA-5fm2A: 41.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A 599 VAL A 607 ALA A 625 LYS A 627 GLU A 644 GLY A 680 LEU A 825 CYH A 835 PHE A 837	748 A1001 (-3.8A) 748 A1001 ( 4.7A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 (-3.3A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A) 748 A1001 (-4.5A) 748 A1001 (-3.7A)	0.45A	4agcA-5grnA: 32.3	4agcA-5grnA: 48.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	LEU A 20 VAL A 28 ALA A 41 LYS A 43 GLU A 61 GLY A 96 LEU A 143	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) ADP A 301 (-2.7A) None None ADP A 301 (-4.7A)	0.63A	4agcA-5hu3A: 22.3	4agcA-5hu3A: 23.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 57 VAL A 65 ALA A 77 GLY A 136 LEU A 187 CYH A 197	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 (-3.4A) IDV A 401 (-4.4A) IDV A 401 (-3.6A)	0.44A	4agcA-5i3oA: 22.3	4agcA-5i3oA: 22.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 30 ALA A 43 LYS A 45 GLU A 61 GLY A 96 LEU A 143	6G2 A 901 ( 4.9A) 6G2 A 901 (-3.2A) 6G2 A 901 ( 3.9A) None 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A)	0.59A	4agcA-5j5tA: 20.5	4agcA-5j5tA: 21.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 LYS A 745 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.53A	4agcA-5j9zA: 30.6	4agcA-5j9zA: 31.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5tur	SERINE/THREONINE-PRO TEIN KINASE PIM-1 (Homo sapiens)	no annotation	7	LEU A 44 VAL A 52 ALA A 65 LYS A 67 GLU A 89 LEU A 93 LEU A 174	None 7LK A 401 (-4.9A) 7LK A 401 (-3.3A) None None None 7LK A 401 (-4.8A)	0.52A	4agcA-5turA: 21.1	4agcA-5turA: 26.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vil	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5 (Homo sapiens)	no annotation	7	LEU A 686 VAL A 694 ALA A 707 LYS A 709 GLU A 725 GLY A 760 LEU A 810	9E1 A1001 (-3.7A) 9E1 A1001 ( 4.0A) 9E1 A1001 (-3.5A) 9E1 A1001 (-2.8A) None 9E1 A1001 (-3.4A) 9E1 A1001 (-4.5A)	0.43A	4agcA-5vilA: 18.0	4agcA-5vilA: 12.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 LYS A 908 GLU A 925 GLY A 962 LEU A1010	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 (-2.8A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.58A	4agcA-6c7yA: 27.7	4agcA-6c7yA: 13.88
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	6	LEU A 730 VAL A 738 ALA A 756 GLU A 775 LEU A 779 VAL A 804	ADN A1104 ( 4.0A) ADN A1104 (-4.4A) ADN A1104 (-3.4A) None None ADN A1104 ( 4.6A)	0.50A	4agcA-6fekA: 31.9	4agcA-6fekA: 23.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fek	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET (Homo sapiens)	no annotation	7	LEU A 730 VAL A 738 ALA A 756 LEU A 779 VAL A 804 GLY A 810 LEU A 881	ADN A1104 ( 4.0A) ADN A1104 (-4.4A) ADN A1104 (-3.4A) None ADN A1104 ( 4.6A) ADN A1104 ( 3.8A) ADN A1104 (-4.3A)	0.58A	4agcA-6fekA: 31.9	4agcA-6fekA: 23.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyl	DUAL SPECIFICITY PROTEIN KINASE CLK2 (Homo sapiens)	no annotation	7	LEU A 169 VAL A 177 ALA A 191 LYS A 193 LEU A 212 GLY A 247 LEU A 297	3NG A 501 (-3.9A) 3NG A 501 ( 4.4A) 3NG A 501 (-3.3A) 3NG A 501 (-3.0A) None None None	1.04A	4agcA-6fylA: 21.7	4agcA-6fylA: undetectable
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fyv	DUAL SPECIFICITY PROTEIN KINASE CLK4 (Homo sapiens)	no annotation	8	LEU A 167 VAL A 175 ALA A 189 LYS A 191 GLU A 206 LEU A 210 GLY A 245 LEU A 295	3NG A 501 (-3.9A) 3NG A 501 ( 4.3A) 3NG A 501 (-3.5A) 3NG A 501 (-2.7A) 3NG A 501 ( 4.7A) None None None	1.15A	4agcA-6fyvA: 21.4	4agcA-6fyvA: undetectable

[["4AGC_A_AXIA2000_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;LYS A 222;GLU A 236;GLY A 272;LEU A 321","None","0.54A","4agcA-1k9aA:30.9","4agcA-1k9aA:29.88"],["4AGC_A_AXIA2000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 267;VAL A 275;ALA A 288;LYS A 290;GLU A 305;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);P16 A   2 (-4.5A);P16 A   2 (-4.2A);P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.47A","4agcA-1opkA:30.2","4agcA-1opkA:28.12"],["4AGC_A_AXIA2000_1","1q8y","Saccharomyces cerevisiae","SR PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A 164;VAL A 172;ALA A 185;LYS A 187;LEU A 206;LEU A 301","ADP A 810 ( 4.3A);ADP A 810 (-4.1A);ADP A 810 (-3.3A);ADP A 810 (-3.1A);None;ADP A 810 (-4.7A)","0.58A","4agcA-1q8yA:20.6","4agcA-1q8yA:23.45"],["4AGC_A_AXIA2000_1","1rjb","Homo sapiens","FL CYTOKINE RECEPTOR","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 818;CYH A 828","None","0.53A","4agcA-1rjbA:42.2","4agcA-1rjbA:47.80"],["4AGC_A_AXIA2000_1","1t46","Homo sapiens","HOMO SAPIENS V-KIT HARDY-ZUCKERMAN 4 FELINE SARCOMA VIRAL ONCOGENE HOMOLOG","PF07714(Pkinase_Tyr)",10,"LEU A 595;VAL A 603;ALA A 621;LYS A 623;GLU A 640;LEU A 644;GLY A 676;LEU A 799;CYH A 809;PHE A 811","STI A   3 ( 3.8A);STI A   3 ( 4.6A);STI A   3 (-3.5A);STI A   3 (-3.7A);STI A   3 (-3.6A);STI A   3 (-4.4A);STI A   3 ( 3.8A);STI A   3 (-4.4A);STI A   3 (-4.5A);STI A   3 (-3.6A)","0.48A","4agcA-1t46A:42.9","4agcA-1t46A:49.44"],["4AGC_A_AXIA2000_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"LEU A 344;VAL A 352;ALA A 367;GLU A 386;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);None;STU A 100 (-3.5A);STU A 100 (-4.5A)","0.49A","4agcA-1u59A:31.0","4agcA-1u59A:30.34"],["4AGC_A_AXIA2000_1","1u5q","Rattus norvegicus","SERINE\/THREONINE PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;GLU A  76;LEU A  80;GLY A 110;LEU A 158","None","0.56A","4agcA-1u5qA:23.2","4agcA-1u5qA:27.97"],["4AGC_A_AXIA2000_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLU A  55;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-4.3A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);None;None;HYM A 400 (-4.5A)","0.50A","4agcA-1zltA:20.5","4agcA-1zltA:23.90"],["4AGC_A_AXIA2000_1","2a2a","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  68","None;None;GOL A3001 (-3.5A);None;None;None","0.53A","4agcA-2a2aA:21.9","4agcA-2a2aA:25.96"],["4AGC_A_AXIA2000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",7,"LEU X  17;VAL X  25;ALA X  37;LYS X  39;GLU X  54;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);STU X 902 (-3.1A);STU X 902 ( 4.4A);STU X 902 (-3.5A);STU X 902 (-4.4A)","0.60A","4agcA-2dq7X:30.7","4agcA-2dq7X:32.93"],["4AGC_A_AXIA2000_1","2eu9","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK3","PF00069(Pkinase)",6,"LEU A 162;VAL A 170;ALA A 184;LYS A 186;GLU A 201;LEU A 205","None","0.58A","4agcA-2eu9A:21.6","4agcA-2eu9A:22.66"],["4AGC_A_AXIA2000_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  59;LEU A  63","ADP A 500 (-4.3A);ADP A 500 (-4.3A);ADP A 500 ( 3.7A);ADP A 500 (-2.9A);None;None","0.53A","4agcA-2f9gA:3.5","4agcA-2f9gA:25.12"],["4AGC_A_AXIA2000_1","2gcd","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE TAO2","PF00069(Pkinase)",6,"VAL A  42;ALA A  55;GLU A  76;LEU A  80;GLY A 110;LEU A 158","STU A 400 ( 4.8A);STU A 400 (-3.2A);None;None;STU A 400 (-3.4A);STU A 400 ( 4.6A)","0.58A","4agcA-2gcdA:24.0","4agcA-2gcdA:26.89"],["4AGC_A_AXIA2000_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  55;VAL A  63;ALA A  76;GLY A 130;LEU A 177;CYH A 190","None","0.37A","4agcA-2hw6A:20.3","4agcA-2hw6A:24.94"],["4AGC_A_AXIA2000_1","2hw6","Homo sapiens","MAP KINASE-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  55;VAL A  63;LYS A  78;LEU A  98;GLY A 130;LEU A 177;CYH A 190","None","0.62A","4agcA-2hw6A:20.3","4agcA-2hw6A:24.94"],["4AGC_A_AXIA2000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;LYS A 271;GLU A 286;GLY A 321;LEU A 370;PHE A 382","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-3.6A);None;GIN A 600 (-4.7A);GIN A 600 (-4.0A)","0.42A","4agcA-2hz0A:31.6","4agcA-2hz0A:35.55"],["4AGC_A_AXIA2000_1","2iwi","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-2","PF00069(Pkinase)",6,"LEU A  38;VAL A  46;ALA A  59;GLU A  83;LEU A  87;LEU A 170","HB1 A1289 ( 4.1A);HB1 A1289 (-3.6A);HB1 A1289 ( 3.7A);None;None;HB1 A1289 (-4.7A)","0.58A","4agcA-2iwiA:21.0","4agcA-2iwiA:24.27"],["4AGC_A_AXIA2000_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"LEU A 588;VAL A 596;ALA A 614;GLU A 633;GLY A 669;LEU A 785","None","0.50A","4agcA-2ogvA:41.0","4agcA-2ogvA:48.31"],["4AGC_A_AXIA2000_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"LEU A 588;VAL A 596;ALA A 614;LYS A 616;GLU A 633;GLY A 669","None","0.53A","4agcA-2ogvA:41.0","4agcA-2ogvA:48.31"],["4AGC_A_AXIA2000_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"LEU A  25;VAL A  33;ALA A  46;LEU A  77;GLY A 109;LEU A 156","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A)","0.47A","4agcA-2phkA:21.8","4agcA-2phkA:23.56"],["4AGC_A_AXIA2000_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"LEU A  25;VAL A  33;LYS A  48;LEU A  77;GLY A 109;LEU A 156","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.2A);None;None;ATP A 381 ( 4.8A)","0.52A","4agcA-2phkA:21.8","4agcA-2phkA:23.56"],["4AGC_A_AXIA2000_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;GLU A 534;VAL A 564;GLY A 570;LEU A 633","None","0.55A","4agcA-2psqA:34.5","4agcA-2psqA:50.00"],["4AGC_A_AXIA2000_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;ALA A 749;LYS A 751;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.58A","4agcA-2r4bA:28.9","4agcA-2r4bA:35.28"],["4AGC_A_AXIA2000_1","2w4k","Homo sapiens","DEATH-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  68","ADP A1303 ( 3.9A);ADP A1303 (-4.0A);ADP A1303 (-3.5A);ADP A1303 (-2.7A);ADP A1303 ( 4.8A);None","0.58A","4agcA-2w4kA:21.9","4agcA-2w4kA:25.00"],["4AGC_A_AXIA2000_1","2xik","Homo sapiens","SERINE\/THREONINE PROTEIN KINASE 25","PF00069(Pkinase)",6,"VAL A  34;ALA A  47;GLU A  66;LEU A  70;GLY A 101;LEU A 147","J60 A1294 ( 4.9A);J60 A1294 (-3.3A);None;None;J60 A1294 ( 3.8A);J60 A1294 (-4.8A)","0.55A","4agcA-2xikA:17.8","4agcA-2xikA:27.08"],["4AGC_A_AXIA2000_1","2yab","Mus musculus","DEATH-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;LYS A  42;GLU A  64;LEU A  68","AMP A1302 (-3.7A);AMP A1302 (-4.2A);AMP A1302 (-3.6A);AMP A1302 (-2.8A);None;None","0.60A","4agcA-2yabA:21.9","4agcA-2yabA:25.67"],["4AGC_A_AXIA2000_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"LEU A  68;VAL A  76;ALA A  92;LYS A  94;GLY A 147;LEU A 194","STU A   1 (-3.8A);None;STU A   1 (-3.3A);STU A   1 (-2.8A);STU A   1 ( 3.9A);STU A   1 (-4.6A)","0.44A","4agcA-2z7rA:21.3","4agcA-2z7rA:27.82"],["4AGC_A_AXIA2000_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 487;VAL A 495;ALA A 515;LYS A 517;VAL A 564;GLY A 570;LEU A 633","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.5A);None;M33 A1996 ( 4.8A);M33 A1996 (-4.5A)","0.46A","4agcA-3b2tA:24.9","4agcA-3b2tA:49.01"],["4AGC_A_AXIA2000_1","3c4f","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",7,"LEU A 484;VAL A 492;ALA A 512;GLU A 531;VAL A 561;GLY A 567;LEU A 630","C4F A   1 ( 3.9A);None;C4F A   1 (-3.3A);None;C4F A   1 ( 4.8A);None;C4F A   1 (-4.6A)","0.59A","4agcA-3c4fA:33.4","4agcA-3c4fA:54.78"],["4AGC_A_AXIA2000_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;LYS A 222;GLU A 236;GLY A 272;LEU A 321","None","0.54A","4agcA-3d7uA:25.2","4agcA-3d7uA:32.01"],["4AGC_A_AXIA2000_1","3f2a","Homo sapiens","PROTO-ONCOGENE SERINE\/THREONINE-PROTEIN KINASE PIM-1","PF00069(Pkinase)",7,"LEU A  44;VAL A  52;ALA A  65;LYS A  67;GLU A  89;LEU A  93;LEU A 174","985 A   1 (-4.1A);985 A   1 (-4.5A);985 A   1 (-3.5A);985 A   1 ( 2.8A); MG A 314 (-3.6A); MG A 314 ( 4.8A);985 A   1 (-4.8A)","0.54A","4agcA-3f2aA:16.3","4agcA-3f2aA:28.00"],["4AGC_A_AXIA2000_1","3hng","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",11,"LEU A 833;VAL A 841;ALA A 859;LYS A 861;GLU A 878;LEU A 882;VAL A 909;GLY A 915;LEU A1029;CYH A1039;PHE A1041","8ST A2001 ( 4.7A);8ST A2001 ( 4.6A);8ST A2001 ( 3.8A);8ST A2001 (-4.0A);8ST A2001 (-3.7A);None;8ST A2001 (-4.1A);None;None;8ST A2001 (-4.2A);8ST A2001 ( 3.7A)","0.51A","4agcA-3hngA:42.0","4agcA-3hngA:67.22"],["4AGC_A_AXIA2000_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",7,"LEU A  49;VAL A  57;ALA A  70;GLU A  91;LEU A  95;GLY A 126;LEU A 173","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;None;XFE A 351 (-4.6A)","0.52A","4agcA-3mvjA:20.8","4agcA-3mvjA:25.06"],["4AGC_A_AXIA2000_1","3mvj","Homo sapiens","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase)",6,"LEU A  49;VAL A  57;ALA A  70;LYS A  72;GLU A  91;LEU A  95","XFE A 351 (-4.2A);XFE A 351 ( 4.5A);XFE A 351 (-3.2A);None;None;None","0.52A","4agcA-3mvjA:20.8","4agcA-3mvjA:25.06"],["4AGC_A_AXIA2000_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",7,"LEU A  88;VAL A  96;ALA A 109;LYS A 111;GLU A 130;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 ( 4.7A);JOZ A 361 (-3.4A);SO4 A   5 (-2.8A);SO4 A   5 (-3.1A);None;None","0.51A","4agcA-3nuuA:22.6","4agcA-3nuuA:25.21"],["4AGC_A_AXIA2000_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 192;VAL A 200;ALA A 213;LYS A 215;GLU A 234;LEU A 238;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;None;None;AMP A 577 (-4.8A)","0.76A","4agcA-3nyoA:21.1","4agcA-3nyoA:22.03"],["4AGC_A_AXIA2000_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;ALA A 751;LYS A 753;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);03Q A   1 (-4.7A);03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.50A","4agcA-3pp0A:29.7","4agcA-3pp0A:28.47"],["4AGC_A_AXIA2000_1","3q5i","Plasmodium berghei","PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",7,"LEU A  63;VAL A  71;ALA A  84;LYS A  86;LEU A 119;GLY A 150;LEU A 197","ANP A1634 ( 4.3A);ANP A1634 (-4.1A);ANP A1634 (-3.6A);ANP A1634 (-3.1A);None;None;ANP A1634 (-4.4A)","0.55A","4agcA-3q5iA:19.6","4agcA-3q5iA:22.57"],["4AGC_A_AXIA2000_1","3tt0","Homo sapiens","BASIC FIBROBLAST GROWTH FACTOR RECEPTOR 1","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;GLU A 531;VAL A 561;GLY A 567;LEU A 630","07J A   1 ( 4.3A);07J A   1 (-4.0A);07J A   1 (-3.5A);07J A   1 (-4.5A);07J A   1 (-3.8A);07J A   1 (-4.7A);07J A   1 (-3.7A);07J A   1 ( 4.4A)","0.60A","4agcA-3tt0A:34.6","4agcA-3tt0A:50.26"],["4AGC_A_AXIA2000_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 361;VAL A 369;ALA A 382;GLU A 403;LEU A 407;GLY A 439;LEU A 486","07U A   1 ( 4.8A);07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 ( 4.8A);None;None;07U A   1 (-4.3A)","0.68A","4agcA-3txoA:13.1","4agcA-3txoA:23.89"],["4AGC_A_AXIA2000_1","3txo","Homo sapiens","PROTEIN KINASE C ETA TYPE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 361;VAL A 369;ALA A 382;LYS A 384;GLU A 403;LEU A 407;LEU A 486","07U A   1 ( 4.8A);07U A   1 (-4.8A);07U A   1 (-3.3A);07U A   1 (-3.0A);07U A   1 ( 4.8A);None;07U A   1 (-4.3A)","0.65A","4agcA-3txoA:13.1","4agcA-3txoA:23.89"],["4AGC_A_AXIA2000_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;LEU A 889;VAL A 916;GLY A 922;LEU A1035;CYH A1045","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;4TT A2001 (-3.7A);4TT A2001 (-4.8A);None","0.44A","4agcA-3vidA:30.0","4agcA-3vidA:85.96"],["4AGC_A_AXIA2000_1","3vid","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",7,"LEU A 840;VAL A 848;ALA A 866;LYS A 868;GLU A 885;LEU A 889;VAL A 916","4TT A2001 ( 4.0A);4TT A2001 ( 4.5A);4TT A2001 (-3.5A);None;None;None;None","0.56A","4agcA-3vidA:30.0","4agcA-3vidA:85.96"],["4AGC_A_AXIA2000_1","3wzd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",9,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;LEU A 889;VAL A 916;GLY A 922;LEU A1035;CYH A1045","LEV A1201 ( 3.8A);LEV A1201 ( 4.9A);LEV A1201 (-3.5A);LEV A1201 (-3.7A);LEV A1201 ( 4.4A);LEV A1201 ( 4.6A);LEV A1201 (-3.6A);LEV A1201 (-4.8A);GOL A1210 ( 3.3A)","0.46A","4agcA-3wzdA:38.3","4agcA-3wzdA:100.00"],["4AGC_A_AXIA2000_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"ILE A 804;LEU A 840;VAL A 848;ALA A 866;GLU A 885;VAL A 916;GLY A 922;LEU A1035;CYH A1045;PHE A1047","None;B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);None;B49 A2000 (-4.8A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A);B49 A2000 ( 4.1A);B49 A2000 (-4.0A)","0.42A","4agcA-4agdA:48.6","4agcA-4agdA:100.00"],["4AGC_A_AXIA2000_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"ILE A 804;LEU A 840;VAL A 848;ALA A 866;LYS A 868;GLU A 885;GLY A 922;LEU A1035;CYH A1045;PHE A1047","None;B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);B49 A2000 (-3.0A);None;B49 A2000 ( 3.7A);B49 A2000 (-4.5A);B49 A2000 ( 4.1A);B49 A2000 (-4.0A)","0.52A","4agcA-4agdA:48.6","4agcA-4agdA:100.00"],["4AGC_A_AXIA2000_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"LEU A 840;VAL A 848;ALA A 866;GLU A 885;LEU A 889;VAL A 916;GLY A 922;LEU A1035;CYH A1045;PHE A1047","B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);None;None;B49 A2000 (-4.8A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A);B49 A2000 ( 4.1A);B49 A2000 (-4.0A)","0.45A","4agcA-4agdA:48.6","4agcA-4agdA:100.00"],["4AGC_A_AXIA2000_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",10,"LEU A 840;VAL A 848;ALA A 866;LYS A 868;GLU A 885;LEU A 889;GLY A 922;LEU A1035;CYH A1045;PHE A1047","B49 A2000 (-3.7A);None;B49 A2000 (-3.5A);B49 A2000 (-3.0A);None;None;B49 A2000 ( 3.7A);B49 A2000 (-4.5A);B49 A2000 ( 4.1A);B49 A2000 (-4.0A)","0.56A","4agcA-4agdA:48.6","4agcA-4agdA:100.00"],["4AGC_A_AXIA2000_1","4agu","Homo sapiens","CYCLIN-DEPENDENT KINASE-LIKE 1","PF00069(Pkinase)",7,"VAL A  18;ALA A  31;LYS A  33;GLU A  51;LEU A  55;LEU A 133;CYH A 143","D15 A 500 (-4.6A);D15 A 500 (-3.4A);D15 A 500 ( 4.1A);None;None;D15 A 500 (-4.5A);D15 A 500 ( 4.0A)","0.60A","4agcA-4aguA:22.2","4agcA-4aguA:25.43"],["4AGC_A_AXIA2000_1","4aw2","Rattus norvegicus","SERINE\/THREONINE-PROTEIN KINASE MRCK ALPHA","PF00069(Pkinase);PF00433(Pkinase_C)",7,"VAL A  91;ALA A 104;LYS A 106;GLU A 125;LEU A 129;GLY A 160;LEU A 208","None;EDO A1420 (-3.4A);EDO A1419 (-3.3A);EDO A1419 (-3.0A);None;None;EDO A1420 ( 4.8A)","0.68A","4agcA-4aw2A:19.3","4agcA-4aw2A:22.60"],["4AGC_A_AXIA2000_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;VAL A 254;ALA A 267;GLU A 288;LEU A 292;GLY A 324;LEU A 371","None","0.75A","4agcA-4c0tA:22.0","4agcA-4c0tA:16.94"],["4AGC_A_AXIA2000_1","4c0t","Candida albicans","LIKELY PROTEIN KINASE","PF00069(Pkinase)",7,"LEU A 246;VAL A 254;ALA A 267;LYS A 269;LEU A 292;GLY A 324;LEU A 371","None","0.60A","4agcA-4c0tA:22.0","4agcA-4c0tA:16.94"],["4AGC_A_AXIA2000_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 663;VAL A 671;ALA A 684;LYS A 686;GLY A 743;LEU A 789","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);AGS A1985 (-3.0A);None;AGS A1985 (-4.8A)","0.52A","4agcA-4crsA:15.2","4agcA-4crsA:23.76"],["4AGC_A_AXIA2000_1","4eut","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLU A  55;LEU A  59;GLY A  92","BX7 A 401 (-3.7A);BX7 A 401 (-4.4A);BX7 A 401 (-3.4A);BX7 A 401 ( 4.0A);None;None;BX7 A 401 (-3.5A)","0.51A","4agcA-4eutA:19.3","4agcA-4eutA:22.09"],["4AGC_A_AXIA2000_1","4euu","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE TBK1","PF00069(Pkinase)",7,"LEU A  15;VAL A  23;ALA A  36;LYS A  38;GLU A  55;LEU A  59;GLY A  92","BX7 A 401 (-3.9A);BX7 A 401 ( 4.6A);BX7 A 401 (-3.4A);BX7 A 401 (-3.5A);None;None;BX7 A 401 (-3.3A)","0.43A","4agcA-4euuA:21.6","4agcA-4euuA:24.74"],["4AGC_A_AXIA2000_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;LYS A 402;GLU A 420;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.89A","4agcA-4f4pA:30.0","4agcA-4f4pA:34.39"],["4AGC_A_AXIA2000_1","4f99","Homo sapiens","CELL DIVISION CYCLE 7-RELATED PROTEIN KINASE","PF00069(Pkinase)",6,"VAL A  72;ALA A  88;LYS A  90;GLU A 104;LEU A 108;LEU A 184","ADP A 601 (-4.0A);ADP A 601 (-3.5A);ADP A 601 (-2.6A);None;None;ADP A 601 ( 4.9A)","0.55A","4agcA-4f99A:13.7","4agcA-4f99A:22.34"],["4AGC_A_AXIA2000_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1122;VAL A1130;ALA A1148;LYS A1150;GLU A1167;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);0UV A1501 (-3.7A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.88A","4agcA-4fodA:24.4","4agcA-4fodA:33.43"],["4AGC_A_AXIA2000_1","4g3f","Mus musculus","NF-KAPPA-BETA-INDUCING KINASE","PF00069(Pkinase)",6,"VAL A 416;ALA A 429;GLU A 442;GLY A 477;LEU A 524;CYH A 535","0WB A 701 (-4.4A);0WB A 701 (-3.3A);0WB A 701 (-3.2A);0WB A 701 ( 4.5A);0WB A 701 (-4.3A);0WB A 701 ( 3.7A)","0.53A","4agcA-4g3fA:21.3","4agcA-4g3fA:25.33"],["4AGC_A_AXIA2000_1","4gv1","Homo sapiens","RAC-ALPHA SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 156;VAL A 164;ALA A 177;LYS A 179;GLU A 198;LEU A 202;GLY A 233","0XZ A 501 ( 4.1A);0XZ A 501 (-4.5A);0XZ A 501 (-3.3A);GOL A 503 ( 2.8A);GOL A 503 (-3.6A);None;None","0.67A","4agcA-4gv1A:20.6","4agcA-4gv1A:23.20"],["4AGC_A_AXIA2000_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"LEU A 828;VAL A 836;ALA A 853;LYS A 855;GLU A 871;GLY A 908;LEU A 956","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-3.5A);None;19S A1201 ( 3.8A);19S A1201 (-4.5A)","0.44A","4agcA-4hviA:29.8","4agcA-4hviA:31.32"],["4AGC_A_AXIA2000_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259","None","0.43A","4agcA-4hzsA:27.0","4agcA-4hzsA:30.81"],["4AGC_A_AXIA2000_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;VAL A 140;ALA A 156;LYS A 158;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.47A","4agcA-4id7A:29.4","4agcA-4id7A:33.62"],["4AGC_A_AXIA2000_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",7,"LEU A 406;VAL A 414;LYS A 429;GLU A 440;GLY A 475;LEU A 522;CYH A 533","T28 A 701 (-3.8A);T28 A 701 (-4.7A);T28 A 701 ( 3.8A);None;T28 A 701 ( 3.0A);T28 A 701 (-3.9A);T28 A 701 (-3.7A)","0.74A","4agcA-4idtA:21.5","4agcA-4idtA:26.84"],["4AGC_A_AXIA2000_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",6,"LEU A  18;VAL A  26;ALA A  39;LYS A  41;GLY A  95;LEU A 143","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 (-2.7A);631 A 301 ( 3.7A);631 A 301 (-4.0A)","0.53A","4agcA-4jxfA:8.5","4agcA-4jxfA:23.76"],["4AGC_A_AXIA2000_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",8,"LEU A 478;VAL A 486;ALA A 506;LYS A 508;GLU A 525;VAL A 555;GLY A 561;LEU A 624","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 (-2.7A);ACP A 801 ( 4.8A);ACP A 801 (-4.7A);ACP A 801 ( 4.6A);ACP A 801 (-4.4A)","0.63A","4agcA-4k33A:25.9","4agcA-4k33A:51.55"],["4AGC_A_AXIA2000_1","4l52","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 7, TGF-BETA-ACTIVATED KINASE 1 AND MAP3K7-BINDING PROTEIN 1 CHIMERA","PF07714(Pkinase_Tyr)",7,"VAL A  50;ALA A  61;GLU A  77;LEU A  81;GLY A 110;LEU A 163;CYH A 174","1UL A 501 ( 4.9A);1UL A 501 (-3.1A);None;None;1UL A 501 ( 3.7A);1UL A 501 (-4.3A);1UL A 501 (-3.6A)","0.62A","4agcA-4l52A:19.2","4agcA-4l52A:28.01"],["4AGC_A_AXIA2000_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",7,"VAL B  38;ALA B  51;LYS B  53;GLU B  70;LEU B  74;GLY B 105;LEU B 151","ADP B 500 (-4.5A);ADP B 500 (-3.3A);ADP B 500 (-3.1A);None;None;None;ADP B 500 (-4.7A)","0.75A","4agcA-4o27B:17.1","4agcA-4o27B:25.91"],["4AGC_A_AXIA2000_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"LEU A  46;VAL A  54;ALA A  67;LYS A  69;GLU A  85;GLY A 128;LEU A 180;CYH A 190","SIN A 401 ( 3.9A);None;SIN A 401 ( 3.7A);None;None;SIN A 401 (-3.5A);SIN A 401 ( 4.5A);None","0.68A","4agcA-4o38A:20.0","4agcA-4o38A:24.56"],["4AGC_A_AXIA2000_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;GLU A 947;GLY A 984;LEU A1030","2TT A1202 (-3.5A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);None;2TT A1202 (-3.4A);2TT A1202 (-4.4A)","0.45A","4agcA-4oliA:27.5","4agcA-4oliA:24.92"],["4AGC_A_AXIA2000_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 627;VAL A 635;ALA A 648;LEU A 673;GLY A 707;LEU A 753","None","0.53A","4agcA-4otdA:21.2","4agcA-4otdA:26.78"],["4AGC_A_AXIA2000_1","4q9z","Homo sapiens","HUMAN PROTEIN KINASE C THETA","PF00069(Pkinase);PF00433(Pkinase_C)",6,"LEU A 386;VAL A 394;ALA A 407;LYS A 409;LEU A 432;LEU A 511","PZW A 801 (-3.9A);PZW A 801 (-4.6A);PZW A 801 (-3.5A);None;None;PZW A 801 (-4.8A)","0.57A","4agcA-4q9zA:19.6","4agcA-4q9zA:24.64"],["4AGC_A_AXIA2000_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",9,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-3.8A);None;P30 A1001 (-3.4A);P30 A1001 (-3.4A);P30 A1001 (-3.6A);P30 A1001 (-3.4A);P30 A1001 (-4.6A);P30 A1001 (-4.1A);P30 A1001 (-3.9A)","0.30A","4agcA-4rt7A:31.3","4agcA-4rt7A:43.33"],["4AGC_A_AXIA2000_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",7,"LEU A 104;VAL A 112;ALA A 125;LYS A 127;GLU A 146;GLY A 181;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);ATP A 501 (-2.6A);None;None;ATP A 501 (-4.5A)","0.56A","4agcA-4wb7A:20.6","4agcA-4wb7A:23.57"],["4AGC_A_AXIA2000_1","4wb7","Homo sapiens","DNAJ HOMOLOG SUBFAMILY B MEMBER 1,CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA","PF00069(Pkinase);PF00226(DnaJ)",7,"LEU A 104;VAL A 112;ALA A 125;LYS A 127;LEU A 150;GLY A 181;LEU A 228","ATP A 501 ( 4.3A);ATP A 501 (-4.0A);ATP A 501 (-3.4A);ATP A 501 (-2.6A);None;None;ATP A 501 (-4.5A)","0.60A","4agcA-4wb7A:20.6","4agcA-4wb7A:23.57"],["4AGC_A_AXIA2000_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;VAL A 201;ALA A 214;LYS A 216;LEU A 239;GLY A 270;LEU A 321","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.62A","4agcA-4wboA:22.0","4agcA-4wboA:21.21"],["4AGC_A_AXIA2000_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",6,"LEU A  52;VAL A  60;ALA A  72;GLY A 132;LEU A 183;CYH A 193","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);KSA A 405 (-3.5A);KSA A 405 (-4.6A);KSA A 405 (-3.4A)","0.36A","4agcA-4wsqA:22.5","4agcA-4wsqA:24.38"],["4AGC_A_AXIA2000_1","4xcu","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"LEU A 473;VAL A 481;ALA A 501;LYS A 503;GLU A 520;VAL A 550","40M A1002 ( 4.6A);40M A1002 ( 4.5A);40M A1002 ( 4.1A);40M A1002 (-4.0A);40M A1002 (-3.7A);40M A1002 (-4.7A)","0.59A","4agcA-4xcuA:33.7","4agcA-4xcuA:47.04"],["4AGC_A_AXIA2000_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;GLU A 661;GLY A 697;LEU A 818;CYH A 828;PHE A 830","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 (-3.1A);P30 A1001 (-3.5A);P30 A1001 (-4.3A);P30 A1001 (-4.8A);P30 A1001 ( 4.1A)","0.59A","4agcA-4xufA:39.1","4agcA-4xufA:51.75"],["4AGC_A_AXIA2000_1","4xuf","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",8,"LEU A 616;VAL A 624;ALA A 642;LYS A 644;GLU A 661;GLY A 697;LEU A 818;PHE A 830","P30 A1001 (-4.0A);P30 A1001 ( 4.8A);P30 A1001 (-3.5A);P30 A1001 ( 4.0A);P30 A1001 (-3.1A);P30 A1001 (-3.5A);P30 A1001 (-4.3A);P30 A1001 ( 4.1A)","0.72A","4agcA-4xufA:39.1","4agcA-4xufA:51.75"],["4AGC_A_AXIA2000_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",8,"LEU A  34;VAL A  42;ALA A  55;LYS A  57;GLU A  76;LEU A  80;GLY A 111;LEU A 158","ADP A 506 ( 3.8A);ADP A 506 (-4.3A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);None;None;None;ADP A 506 (-4.7A)","0.53A","4agcA-4ysjA:21.9","4agcA-4ysjA:23.28"],["4AGC_A_AXIA2000_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",8,"LEU A 484;VAL A 492;ALA A 512;LYS A 514;GLU A 531;VAL A 561;GLY A 567;LEU A 630","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 ( 3.1A);EDO A1766 (-4.1A);38O A1769 (-4.3A);38O A1769 (-3.4A);38O A1769 (-4.6A)","0.60A","4agcA-5a46A:34.6","4agcA-5a46A:45.43"],["4AGC_A_AXIA2000_1","5e8y","Homo sapiens","TGF-BETA RECEPTOR TYPE-2","PF07714(Pkinase_Tyr)",6,"VAL A 258;ALA A 275;LYS A 277;GLY A 331;LEU A 386;CYH A 396","STU A 601 (-4.0A);STU A 601 (-3.1A);STU A 601 (-2.4A);STU A 601 (-3.5A);STU A 601 (-3.9A);STU A 601 (-3.2A)","0.46A","4agcA-5e8yA:24.3","4agcA-5e8yA:27.55"],["4AGC_A_AXIA2000_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",6,"LEU A  99;VAL A 107;ALA A 120;LYS A 122;GLY A 176;LEU A 223","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A)","0.36A","4agcA-5eykA:22.1","4agcA-5eykA:25.94"],["4AGC_A_AXIA2000_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",7,"LEU A 903;VAL A 911;ALA A 928;LYS A 930;GLU A 947;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);None;None;5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.53A","4agcA-5f1zA:28.2","4agcA-5f1zA:28.84"],["4AGC_A_AXIA2000_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;ALA A 756;LYS A 758;GLU A 775;LEU A 779;VAL A 804","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);PP1 A2012 (-3.5A);None;PP1 A2012 (-4.5A)","0.64A","4agcA-5fm2A:32.4","4agcA-5fm2A:41.29"],["4AGC_A_AXIA2000_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;ALA A 756;LYS A 758;LEU A 779;VAL A 804;GLY A 810","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);None;PP1 A2012 (-4.5A);PTR A 809 (-2.4A)","0.65A","4agcA-5fm2A:32.4","4agcA-5fm2A:41.29"],["4AGC_A_AXIA2000_1","5fm2","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","PF07714(Pkinase_Tyr)",7,"LEU A 730;VAL A 738;ALA A 756;LYS A 758;VAL A 804;GLY A 810;LEU A 881","PP1 A2012 (-4.6A);PP1 A2012 (-4.4A);PP1 A2012 (-3.2A);PP1 A2012 (-4.1A);PP1 A2012 (-4.5A);PTR A 809 (-2.4A);PP1 A2012 (-4.6A)","0.61A","4agcA-5fm2A:32.4","4agcA-5fm2A:41.29"],["4AGC_A_AXIA2000_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",9,"LEU A 599;VAL A 607;ALA A 625;LYS A 627;GLU A 644;GLY A 680;LEU A 825;CYH A 835;PHE A 837","748 A1001 (-3.8A);748 A1001 ( 4.7A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 (-3.3A);748 A1001 ( 4.0A);748 A1001 (-4.3A);748 A1001 (-4.5A);748 A1001 (-3.7A)","0.45A","4agcA-5grnA:32.3","4agcA-5grnA:48.40"],["4AGC_A_AXIA2000_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"LEU A  20;VAL A  28;ALA A  41;LYS A  43;GLU A  61;GLY A  96;LEU A 143","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);ADP A 301 (-2.7A);None;None;ADP A 301 (-4.7A)","0.63A","4agcA-5hu3A:22.3","4agcA-5hu3A:23.99"],["4AGC_A_AXIA2000_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  57;VAL A  65;ALA A  77;GLY A 136;LEU A 187;CYH A 197","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 (-3.4A);IDV A 401 (-4.4A);IDV A 401 (-3.6A)","0.44A","4agcA-5i3oA:22.3","4agcA-5i3oA:22.77"],["4AGC_A_AXIA2000_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"VAL A  30;ALA A  43;LYS A  45;GLU A  61;GLY A  96;LEU A 143","6G2 A 901 ( 4.9A);6G2 A 901 (-3.2A);6G2 A 901 ( 3.9A);None;6G2 A 901 (-3.6A);6G2 A 901 (-4.7A)","0.59A","4agcA-5j5tA:20.5","4agcA-5j5tA:21.50"],["4AGC_A_AXIA2000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;LYS A 745;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.53A","4agcA-5j9zA:30.6","4agcA-5j9zA:31.25"],["4AGC_A_AXIA2000_1","5tur","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PIM-1","no annotation",7,"LEU A  44;VAL A  52;ALA A  65;LYS A  67;GLU A  89;LEU A  93;LEU A 174","None;7LK A 401 (-4.9A);7LK A 401 (-3.3A);None;None;None;7LK A 401 (-4.8A)","0.52A","4agcA-5turA:21.1","4agcA-5turA:26.00"],["4AGC_A_AXIA2000_1","5vil","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 5","no annotation",7,"LEU A 686;VAL A 694;ALA A 707;LYS A 709;GLU A 725;GLY A 760;LEU A 810","9E1 A1001 (-3.7A);9E1 A1001 ( 4.0A);9E1 A1001 (-3.5A);9E1 A1001 (-2.8A);None;9E1 A1001 (-3.4A);9E1 A1001 (-4.5A)","0.43A","4agcA-5vilA:18.0","4agcA-5vilA:12.31"],["4AGC_A_AXIA2000_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;LYS A 908;GLU A 925;GLY A 962;LEU A1010","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.58A","4agcA-6c7yA:27.7","4agcA-6c7yA:13.88"],["4AGC_A_AXIA2000_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",6,"LEU A 730;VAL A 738;ALA A 756;GLU A 775;LEU A 779;VAL A 804","ADN A1104 ( 4.0A);ADN A1104 (-4.4A);ADN A1104 (-3.4A);None;None;ADN A1104 ( 4.6A)","0.50A","4agcA-6fekA:31.9","4agcA-6fekA:23.72"],["4AGC_A_AXIA2000_1","6fek","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","no annotation",7,"LEU A 730;VAL A 738;ALA A 756;LEU A 779;VAL A 804;GLY A 810;LEU A 881","ADN A1104 ( 4.0A);ADN A1104 (-4.4A);ADN A1104 (-3.4A);None;ADN A1104 ( 4.6A);ADN A1104 ( 3.8A);ADN A1104 (-4.3A)","0.58A","4agcA-6fekA:31.9","4agcA-6fekA:23.72"],["4AGC_A_AXIA2000_1","6fyl","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK2","no annotation",7,"LEU A 169;VAL A 177;ALA A 191;LYS A 193;LEU A 212;GLY A 247;LEU A 297","3NG A 501 (-3.9A);3NG A 501 ( 4.4A);3NG A 501 (-3.3A);3NG A 501 (-3.0A);None;None;None","1.04A","4agcA-6fylA:21.7","4agcA-6fylA:undetectable"],["4AGC_A_AXIA2000_1","6fyv","Homo sapiens","DUAL SPECIFICITY PROTEIN KINASE CLK4","no annotation",8,"LEU A 167;VAL A 175;ALA A 189;LYS A 191;GLU A 206;LEU A 210;GLY A 245;LEU A 295","3NG A 501 (-3.9A);3NG A 501 ( 4.3A);3NG A 501 (-3.5A);3NG A 501 (-2.7A);3NG A 501 ( 4.7A);None;None;None","1.15A","4agcA-6fyvA:21.4","4agcA-6fyvA:undetectable"]]